Integrative genomics and epigenomics for personalized cancer medicine

已经开发了检测基因组和表观基因组异常的创新技术，并利用这些技术在研究过程中成功识别了许多与癌症相关的基因。特别是，我们确定了10个候选癌基因，包括DUSP26和SMYD2，以及10个候选抑癌基因，包括DBC1和PCDH17。此外，在口腔癌和肝细胞癌中分别成功鉴定了四个抑癌基因miR-13和miR-193a，或表观沉默的miR-124和miR-203。

Innovative techniques for detection of genomic and epigenomic aberrations underlying the pathogenesis have been developed and using those techniques numerous cancer-related genes have been successfully identified during the course of the research program. In particular, we identified 10 candidate oncogenes including DUSP26 and SMYD2 up-regulated due to gene amplification, and 10 candidate tumor suppressor genes including DBC1 and PCDH17. Furthermore four tumor-suppressor microRNAs, miR-13 and miR-193a, or miR-124 and miR-203, epigenetically silenced, were successfully identified in oral cancer or hepatocellular carcinoma, respectively.